Research shows that anti-cancer function can occur by inhibiting the expression of the lipogenic enzyme FASN in Human Epidermal Growth Factor Receptor2 (HER2)-overexpressing breast carcinoma cells, and thus offers a previously unrecognized mechanism for EVOO-related cancer preventive effects (Menendez et al., 2008a). The gene discussed is ERBB2; the disease is breast carcinoma.